Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline ... treating disease by modifying the activity of regulatory T cells, or Tregs. Pandion’s lead candidate PT101 ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...